Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab

A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Sanae, Naganuma, Atsushi, Furuichi, Nozomi, Furusawa, Ai, Kaburagi, Takuya, Naruse, Hiroaki, Tomaru, Shota, Sano, Nozomi, Suzuki, Yuhei, Masuda, Tomoyuki, Hoshino, Takashi, Yasuoka, Hidetoshi, Tanaka, Yuko, Saito, Shuichi, Hatanaka, Takeshi, Kakizaki, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686744/
https://www.ncbi.nlm.nih.gov/pubmed/36927965
http://dx.doi.org/10.2169/internalmedicine.1610-23
Descripción
Sumario:A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pembrolizumab, which is an immune checkpoint inhibitor (ICI), resulted in a partial response, and there were no significant immune-related adverse events. According to recently published reports, the frequency of TMB-high biliary tract cancer (BTC) is 3.4-4%, which makes it extremely rare. In conclusion, ICIs may be effective in patients with TMB-high BTC.

Ejemplares similares